Coloplast’s Q1 report for 2025/26 shows 6% organic growth and 3% EBIT growth. Key areas saw growth: Stoma 4%, Continence 7%, Voice & Respiratory Care 8%, Wound & Tissue Repair 5%, and Urology 8%. Weak start in Stoma due to China and US factors. Urology had strong growth. EBIT was 1.85 billion DKK.

For 2025/26, Coloplast maintains expectations of 7% organic growth, 7% EBIT growth, and 16% return on invested capital. Chronic Care momentum expected to continue. Urology forecasted for high single-digit growth, Kerecis growth revised to 10%, and EBIT margin improvement for Kerecis.

Coloplast’s CEO acknowledges a slow start in 2025 due to challenges in Kerecis, but remains confident in the company’s long-term prospects. Chronic business shows solid growth worldwide, except in China. Urology segment in the US is performing well, with improvements in kidney and bladder diseases.

Read more at GlobeNewswire: Coloplast A/S – Regnskabsmeddelelse, Q1 2025/26